Literature DB >> 21055496

Report of an International collaborative study to establish the first WHO reference reagents for BCG vaccines of three different sub-strains.

Mei M Ho1, Kevin Markey, Peter Rigsby, Jason Hockley, Michael J Corbel.   

Abstract

The WHO First International Reference Preparation for BCG vaccine is over forty years old and is no longer available for distribution due to stock depletion and its significant loss of viability. International consultations identified a demand for replacement with sub-strain specific BCG preparations. An International collaborative study was carried out to evaluate three candidates for WHO Reference Reagent for BCG vaccine of Danish 1331, Russian BCG-I and Tokyo 172-1 sub-strains. These candidates were quantified for viability using both cultural viable count and modified ATP assays. The proposal for the establishment of these First WHO Reference Reagents for BCG vaccines was discussed in the WHO Expert Committee on Biological Standardization meeting, October 2009. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21055496     DOI: 10.1016/j.vaccine.2010.10.066

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Lipid phenotype of two distinct subpopulations of Mycobacterium bovis Bacillus Calmette-Guerin Tokyo 172 substrain.

Authors:  Takashi Naka; Shinji Maeda; Mamiko Niki; Naoya Ohara; Saburo Yamamoto; Ikuya Yano; Jun-Ichi Maeyama; Hisashi Ogura; Kazuo Kobayashi; Nagatoshi Fujiwara
Journal:  J Biol Chem       Date:  2011-10-26       Impact factor: 5.157

2.  Editorial Commentary: Different Strains of Bacillus Calmette-Guérin Vaccine Have Very Different Effects on Tuberculosis and on Unrelated Infections.

Authors:  Frank Shann
Journal:  Clin Infect Dis       Date:  2015-06-09       Impact factor: 9.079

3.  The establishment of sub-strain specific WHO Reference Reagents for BCG vaccine.

Authors:  Belinda Dagg; Jason Hockley; Peter Rigsby; Mei M Ho
Journal:  Vaccine       Date:  2014-10-11       Impact factor: 3.641

4.  Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG.

Authors:  Gloria Esteso; Nacho Aguiló; Esther Julián; Omodele Ashiru; Mei M Ho; Carlos Martín; Mar Valés-Gómez
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

5.  Efficacy and immunogenicity of different BCG doses in BALB/c and CB6F1 mice when challenged with H37Rv or Beijing HN878.

Authors:  Bhagwati Khatri; James Keeble; Belinda Dagg; Daryan A Kaveh; Philip J Hogarth; Mei Mei Ho
Journal:  Sci Rep       Date:  2021-12-02       Impact factor: 4.996

Review 6.  An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.

Authors:  Hamid Motamedi; Marzie Mahdizade Ari; Shirin Dashtbin; Matin Fathollahi; Hadi Hossainpour; Amirhoushang Alvandi; Jale Moradi; Ramin Abiri
Journal:  Int Immunopharmacol       Date:  2021-05-06       Impact factor: 5.714

7.  Deep sequencing analysis of the heterogeneity of seed and commercial lots of the bacillus Calmette-Guérin (BCG) tuberculosis vaccine substrain Tokyo-172.

Authors:  Takayuki Wada; Fumito Maruyama; Tomotada Iwamoto; Shinji Maeda; Taro Yamamoto; Ichiro Nakagawa; Saburo Yamamoto; Naoya Ohara
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

8.  Complete Genome Sequence, Genome Stability and Phylogeny of the Vaccine Strain Mycobacterium bovis BCG SL222 Sofia.

Authors:  Stefan Panaiotov; Yordan Hodzhev; Vladimir Tolchkov; Borislava Tsafarova; Alexander Mihailov; Tzvetelina Stefanova
Journal:  Vaccines (Basel)       Date:  2021-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.